All posts by admin

Business Wire India

LTM, the Business Creativity partner to the world’s largest enterprises, has been recognized as an Innovator in Avasant’s Generative AI Services 2025 RadarView™. The recognition highlights LTM’s strong capabilities in generative AI (Gen AI) and agentic AI, underpinned by robust governance, enterprise-scale platforms, and sustained investments in innovation.

According to the Avasant report, LTM stands out for its centralized Gen AI and agentic AI orchestration ecosystem, with a strong emphasis on AI governance, compliance, and responsible AI adoption. The report notes that LTM continues to strengthen its capabilities across voice AI, edge inferencing, and industry-specific agentic AI solutions, enabling enterprises to move from AI experimentation to scalable, production-grade deployments.

Avasant highlights LTM’s BlueVerse^TM ecosystem as a key differentiator, a modular platform for deploying GenAI and agentic AI that works across various enterprise systems and supports multi-cloud, multi-LLM, and multi-provider setups. The RadarView^TM report also highlighted LTM’s comprehensive AI governance and built-in guardrails for safety, compliance, and adherence to global standards, including GDPR, HIPAA, and ISO.

The report also highlights enterprise case studies demonstrating LTM’s impact on business outcomes, including faster AI risk management, improved decision-making through multi-agent systems, and higher productivity across sectors such as BFSI, manufacturing, energy, healthcare, and professional services. LTM’s strategic partnerships, AI Centers of Excellence, and Gen AI workforce programs strengthen its reputation as a reliable partner for organizations implementing GenAI at scale.

“Organizations today are focused on unlocking real value from GenAI and agentic AI at enterprise scale. Being recognized by Avasant reinforces our commitment to enabling organizations translate AI ambition into real business impact through our BlueVerse^TM ecosystem and deep industry expertise,” said Krishnan Iyer, Chief Growth Officer, LTM.

Abhisekh Satapathy, Principal Analyst, Avasant, added, “Enterprises are shifting toward AI-native operating models built around contextual intelligence, centralized governance, and scalable Gen AI deployments. However, real-world execution is constrained by data readiness gaps, integration complexity across platforms, and the need for robust operational oversight.​

LTM enables this shift through its BlueVerse^TM platform that provides centralized orchestration, governance, and deployment for Gen AI and Agentic AI applications, backed by over 1,000 ready-to-deploy AI agents, embedded LLM guardrails, and prebuilt GenAI deployment templates and solutions across ITOps, software engineering, marketing, and customer engagement. These capabilities are reinforced through partnerships with hyperscalers, LLM vendors, and Gen AI hardware providers, as well as investments in niche AI startups to strengthen capabilities in sovereign AI, voice-native Gen AI, multimodal interaction, and industry-specific multi-AI agent orchestration across sectors such as BFSI, healthcare, and retail and CPG.​

With these capabilities, LTM supports enterprises in orchestrating, governing, and deploying Gen AI and agentic AI solutions across core business workflows, strengthening its position as an Innovator in Avasant’s Generative AI Services 2025 RadarView™.​”

Business Wire India

SLB (NYSE: SLB) continues to closely monitor the unfolding situation in the Middle East and adapt its operations.

 

The safety and security of SLB’s employees is the highest priority, and the company has activated local and regional crisis response teams that are meeting daily. Travel to and transit through the region have been suspended, and the company has begun to demobilize operations in a few countries in response to customer actions to safeguard personnel and facilities. These measures will continue as long as necessary until the environment in the region has stabilized. SLB is working closely with local authorities and its customers to monitor the situation and will begin a phased resumption of full activity as conditions allow.

 

 

SLB revenue for the first quarter will be lower than expected, and the company expects to incur additional costs resulting in an impact of approximately 6-9 cents of earnings per diluted share for the first quarter. Given the dynamic nature of the environment, these factors could change, and we will continue to closely monitor developments and their impact.

 

 

Despite these near-term disruptions, SLB remains confident in the underlying resilience of its global business, including the Middle East. The company has dealt with numerous geopolitical crises throughout its 100-year history and has deep experience navigating these challenges while remaining focused on serving its global customer base.

 

 

About SLB

 

 

SLB (NYSE: SLB) is a global technology company that has driven energy innovation for 100 years. With a global footprint in more than 100 countries and employees representing almost twice as many nationalities, we work each day on innovating oil and gas, delivering digital at scale, decarbonizing industries, and developing and scaling new energy systems that accelerate the energy transition. Find out more at slb.com.

 

 

Cautionary Statement Regarding Forward-looking Statements

 

 

This Form 8-K and the press release furnished as Exhibit 99 hereto, as well as other statements we make, contain “forward-looking statements” within the meaning of the federal securities laws, which include any statements that are not historical facts. Such statements often contain words such as “expect,” “may,” “can,” “believe,” “predict,” “plan,” “potential,” “projected,” “projections,” “precursor,” “forecast,” “outlook,” “expectations,” “estimate,” “intend,” “anticipate,” “ambition,” “goal,” “target,” “scheduled,” “think,” “should,” “could,” “would,” “will,” “see,” “likely,” and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as statements about our financial and performance targets and other forecasts or expectations regarding, or dependent on, our business outlook; future global economic and geopolitical conditions; future liquidity, including free cash flow; and future results of operations. These statements are subject to risks and uncertainties, including, but not limited to, changing global economic and geopolitical conditions; changes in exploration and production spending by our customers, and changes in the level of oil and natural gas exploration and development; the results of operations and financial condition of our customers and suppliers; the inability to achieve our financial and performance targets and other forecasts and expectations; the inability to achieve our net-zero carbon emissions goals or interim emissions reduction goals; general economic, geopolitical, and business conditions in key regions of the world; foreign currency risk; inflation; changes in monetary policy by governments; tariffs; pricing pressure; weather and seasonal factors; unfavorable effects of health pandemics; availability and cost of raw materials; operational modifications, delays, or cancellations; challenges in our supply chain; production declines; the extent of future charges; the inability to recognize efficiencies and other intended benefits from our business strategies and initiatives, such as digital or new energy, as well as our cost reduction strategies; changes in government regulations and regulatory requirements, including those related to offshore oil and gas exploration, radioactive sources, explosives, chemicals, and climate-related initiatives; the inability of technology to meet new challenges in exploration; the competitiveness of alternative energy sources or product substitutes; and other risks and uncertainties detailed in this Form 8-K and the presentation furnished hereto and our most recent Forms 10-K, 10-Q, and 8-K filed with or furnished to the SEC.

 

 

If one or more of these or other risks or uncertainties materialize (or the consequences of any such development changes), or should our underlying assumptions prove incorrect, actual results or outcomes may vary materially from those reflected in our forward-looking statements. Statements in this Form 8-K and the press release furnished hereto are made as of the date hereof, and SLB disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events, or otherwise.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310710904/en/

 

Business Wire India

Veristat, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced expanded regulatory and clinical trial services to international pharmaceutical and medical device companies seeking a streamlined path into European, including the United Kingdom and Switzerland, plus Australian, Canadian, and U.S. markets. Particularly, Veristat has helped many Chinese companies – including Hansoh Pharma and CStone Pharmaceuticals – successfully navigate regional regulatory requirements and legal complexities leading to product approvals. Now, Veristat is expanding to provide comprehensive regional clinical trial support.

 

China is the world’s second-largest drug producer but has traditionally focused on domestic commercialization. Today, that is changing. Nearly half of all new drug molecules in human trials worldwide now originate from China, and Morgan Stanley projects annual revenue from Chinese-originated drugs could reach $34 billion by 2030 and $220 billion by 2040. Due to recent policy changes that open new opportunity for China, it is expected to become a major hub for licensing deals for international commercialization. But before the ‘sleeping giant’ can awaken, it needs regulatory and, sometimes, clinical development support in local markets.

 

Veristat provides Chinese drug and device companies with trusted regulatory services to bring novel therapies already approved domestically through regional regulatory pathways for approval across Europe, the UK, Switzerland, the US, Canada, and Australia. The American-based CRO has extensive experience preparing, submitting, and obtaining approvals for Marketing Authorization Applications (MAA) and New Drug Applications (NDAs), often based largely on foreign data. Veristat can also serve as the applicant to enable companies without a legal presence in these regions to quickly and efficiently submit their regulatory dossiers.

 

“Veristat has the deep understanding of the regulatory landscape needed to support foreign organizations with entry to key markets. Our team really enjoyed working with the Veristat team, as they always supported with prompt responses, flexibility, and recommendations on problem-solving,” said Li Zhang, Regulatory Affairs at CStone Pharmaceuticals.

 

Veristat’s multidisciplinary team conducts a thorough Gap Analysis of each customer’s data package, recommends the most efficient regulatory strategy, and guides the best path to approval across countries. This includes identifying and generating any additional analyses required, as well as compiling or developing the necessary data for submission to the relevant agencies. For instance, Veristat offers comprehensive clinical trial execution support for foreign companies whose domestic clinical trial data is not sufficient for local regulatory requirements.

 

“Veristat has had tremendous success for China-based customers recently, securing approvals in the US, EU, and UK. These successes were achieved through comprehensive dossier development and effective negotiations with EMA, MHRA, and FDA,” explained Daphne Smyth, Vice President of Global Regulatory Affairs at Veristat. “We also support subsequent submissions in Canada, Switzerland, Australia, and other regions globally, and provide comprehensive assistance throughout the entire agency review process.”

 

Between 2020 and 2025, Veristat submitted 68 initial INDs and DMFs, 10 initial Food and Drug Administration (FDA) marketing applications, and 8 initial EMA/MHRA/Swissmedic marketing applications. With 30 years of supporting more than 100 regulatory approvals, the full-service CRO has deep experience in rare disease, neurological disease, oncology, and advanced medicines including cell and gene therapies.

 

Veristat will be attending BIO China (March 12-14) and CMAC (March 18-20) both in Suzhou, China, where companies can learn more about its international service offering. Email Lorenzo.scalise@veristat.com to arrange a meeting.

 

About Veristat

 

Veristat is a full-service CRO and consultancy that helps life sciences companies bring novel therapies to market fast. With 30 years of experience and support in more than 100 regulatory approvals and deep expertise in rare disease, neurological disease, oncology, and advanced therapies, Veristat integrates strategic planning, regulatory insight, and trial execution to overcome complex challenges and accelerate success. From early planning through approval, Veristat delivers tailored solutions that drive meaningful outcomes for patients worldwide.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311570116/en/

 

Business Wire India

 

Highlights

 

• Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers¹, ensuring patients retain continuity of care while reducing carbon emissions
• Bespak’s leadership in low-GWP propellant inhaler manufacturing along with significant expansion at its Holmes Chapel site strengthens Chiesi’s global supply chain resilience
• Partnership aligns with the science-based climate commitments of both companies

 

Chiesi Group (“Chiesi”), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311319953/en/

 

 

 

Building on years of collaboration, the agreement reflects a shared long-term vision: delivering lower carbon inhaled therapies through CMIs at scale, without compromising clinical choice or continuity of care for patients. Both companies are committed to addressing climate change through measurable, science-based action. Chiesi’s ambition to reach Net Zero targets by 2035, and Bespak’s validated decarbonization roadmap, underpin a partnership grounded in shared sustainability principles.

 

Maria Paola Chiesi, Chiesi Group Vice Chair, said: “At Chiesi, sustainability is not an add-on; it is a commitment that guides our strategic choices. We know that inhalers are essential treatments, and that the environmental impact associated with them must be addressed without shifting the burden onto patients. The partnership with Bespak reinforces our efforts to reduce emissions across the value chain, while protecting access, quality and trust. Climate action and patient care must continue to advance hand in hand.”

 

 

To meet the needs of patients and reduce impact on the environment, Chiesi is working to be the only company to offer a portfolio of extrafine formulation Carbon Minimal Inhalers, including both dry powder inhalers (DPIs) and next generation propellant pMDIs. Chiesi’s CMI program is designed to significantly reduce the carbon footprint of pMDIs by up to 90%, through the transition to a next-generation, low global warming potential (GWP) propellant, while maintaining established treatment options and device familiarity for patients. Reinforcing the partnership with Bespak adds industrial scale and resilience to Chiesi’s journey, supporting a phased and responsible transition.

 

 

The expanded collaboration further strengthens Bespak’s position at the forefront of the global industry’s transition to next-generation, low-GWP propellants, and its Holmes Chapel site as a specialist pMDI manufacturing hub within the global pharmaceutical supply chain. Positioned in the North West of England’s inhalation R&D and manufacturing cluster, the site contributes high value skills, advanced technical expertise and long-term investment in sustainable inhaler manufacturing, for the benefit of patients and healthcare systems worldwide.

 

 

Giuseppe Accogli, Chiesi Group CEO, added:“This agreement strengthens an already established partnership with Bespak, and is a concrete example of how we translate our ambition into action. By working with trusted partners across our value chain, we can deliver sustainable innovation at scale while ensuring that patients receive their needed therapies.”

 

 

Chris Hirst, Bespak CEO, said: “Our collaboration with Chiesi has grown over time around a shared commitment to patient safety, technical excellence and sustainability. By deepening this partnership, we are accelerating the transition to low carbon pMDIs and reinforcing the UK’s role as a center of excellence for sustainable inhalation manufacturing. This is a position being recognized by the wider industry, leading to our Holmes Chapel site being selected as a key source of supply by leading brand owners like Chiesi, cementing our role as a strategic supply chain partner for the next generation propellant inhalers and innovative nasally-delivered therapies.”

 

 

About Chiesi Group

 

 

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By adopting the legal form of Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group’s research and development center in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

 

 

For more information, visit chiesi.com or the website of your local Chiesi affiliate.

 

 

About Bespak

 

 

Bespak is a specialist inhalation contract development and manufacturing organisation (CDMO) focused on pulmonary and nasal drug delivery. Trusted by the world’s leading pharmaceutical companies, Bespak delivers end-to-end capabilities across product development, clinical supply and commercial manufacturing of inhaled therapies for global supply.

 

 

Headquartered in Holmes Chapel, UK, with specialist manufacturing sites in Holmes Chapel and King’s Lynn, UK, Bespak develops and supplies pressurised metered dose inhaler (pMDI) products, valves and actuators, complex dry powder inhaler (DPI) devices, nasal products and devices, and supports emerging inhalation technologies, including innovative soft mist systems.

 

 

Sustainability underpins every step of how Bespak operates and innovates. The company has taken clear and measurable steps to align with key United Nations (UN) Sustainable Development Goals (SDGs), is a signatory of the United Nations Global Compact (UNGC) and has set approved net-zero and near-term company-wide emissions targets with the Science Based Targets initiative (SBTi).

 

 

Through collaboration and targeted investment, Bespak is accelerating the industry’s transition to more sustainable inhaled medicines.

 

 

Built on a long history of inhalation experience and ready for the future, Bespak is a long-term innovation partner creating lasting impact for patients and the planet.

 

 

_________________________

1 In a limited number of countries, including the United Kingdom, non‑extrafine products will also be transitioned to CMI.

 

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311319953/en/

 

Business Wire India

• NTT DATA drives success in healthcare, manufacturing and other sectors with NVIDIA-powered technologies
• NTT DATA AI solutions now integrate NVIDIA AI Enterprise software, including NVIDIA NeMo and NIM Microservices to create a full-stack, production-ready, GPU-accelerated agentic AI platform

 

NTT DATA, a global leader in AI, digital business and technology services, announced an initiative to deliver NVIDIA-powered enterprise AI factories that drive innovation and operational excellence for organizations worldwide. NTT DATA’s new enterprise AI factories provide full-stack, domain-specific solutions that integrate data, infrastructure, workflows and governance to give organizations a repeatable and production-ready operating model for enterprise AI.

 

NTT DATA enterprise AI factories, powered by NVIDIA, are adaptive, intelligent and automated ecosystems designed to help clients accelerate return on investment by scaling enterprise AI efficiently and managing the full AI lifecycle end to end. The company’s new enterprise AI factories integrate the NVIDIA AI infrastructure—combining GPU-accelerated computing and high-performance networking—with NVIDIA AI Enterprise software, including NVIDIA NIM microservices, to deliver high‑throughput, low‑latency AI that can be deployed consistently across cloud, data center and edge environments. Through NTT DATA’s advanced solutions and services, this enables scalable model training, inference and enterprise AI application development.

 

 

Building on NTT DATA’s end-to-end capabilities and deep industry expertise, the NVIDIA-powered enterprise AI factories are purpose-built to meet domain-specific requirements at industry scale. This enables organizations to drive faster innovation, optimize operations, enhance knowledge management and support data-driven decision-making while reducing risk and time to value.

 

 

“Visionary enterprises are redesigning core workflows end to end with AI, and they need trusted partners working in unison to achieve transformative and measurable results,” said Abhijit Dubey, CEO, NTT DATA, Inc. “By integrating NVIDIA technologies into our enterprise AI factories, we’re giving clients a powerful, standardized and secure environment to adopt agentic AI with measurable returns from the start.”

 

 

NTT DATA Real-World Deployments Demonstrate Measurable Impact

 

 

Early adopters are demonstrating how NTT DATA is deploying NVIDIA AI infrastructure to translate advanced AI capabilities into real-world, domain-specific impact. Examples include:

 

 

• Healthcare: A leading cancer-research hospital is working with NTT DATA and Dell to use NVIDIA HGX platforms for advanced radiology analysis and rapid model evaluation, supporting clinical research and diagnostic workflows.
• Automotive Manufacturing: A global automotive supplier partnered with NTT DATA to accelerate smart factory modernization using GPU as a Service powered by NVIDIA AI infrastructure. This manufacturer reduced production setup time from months to days by validating workloads on bare metal and then scaling them via an AI-factory architecture.
• Technology Manufacturing: A U.S.-based advanced manufacturing company is working with NTT DATA to virtually validate a next-generation battery production line using NVIDIA-accelerated simulation and 3D visualization. Modeling material flow, automation logic and production scenarios before physical deployment reduces commissioning risk, improves throughput and establishes a scalable foundation for future digital factory expansion.

 

 

NTT DATA Integrates NVIDIA NeMo and NIM Microservices

 

NTT DATA also has expanded NTT DATA AI solutions by integrating NVIDIA NeMo, a modular software suite for building, customizing, and managing enterprise-scale agentic AI systems on GPU-accelerated infrastructure, and NVIDIA NIM microservices, which provide prebuilt, GPU‑optimized containers with industry‑standard APIs for fast, reliable deployment of AI applications at scale.

 

 

NTT DATA offers integrated, prequalified GenAI prototypes and solutions that standardize output, minimize complexity, reduce risk, speed adoption and accelerate return. With the integration of NeMo and NIM, NTT DATA AI solutions provide a full-stack, production-ready, GPU-accelerated AI agent platform.

 

 

“Organizations worldwide are moving from isolated model adoption to intelligent AI solutions and platforms, often complementing GenAI with agents that reason, act and adapt within enterprise systems,” said Yutaka Sasaki, President and CEO, NTT DATA Group. “Embedding NVIDIA technologies into our platforms accelerates innovation while giving clients the performance, control and compliance they require.”

 

 

“Enterprises are now seeking robust, scalable platforms that can successfully transition their AI initiatives from pilot projects to full-scale production,” said John Fanelli, Vice President, Enterprise Software, NVIDIA. “NTT DATA’s AI factory offerings, built on the NVIDIA full-stack platform, provide clients with the domain-specific solutions needed to confidently achieve production-grade enterprise AI at scale.”

 

 

NTT DATA Builds on Longstanding Foundation of Innovation with NVIDIA Technology

 

 

NTT DATA is the only global IT services provider that is active across NVIDIA’s Solution Provider, Cloud Partner and Global System Integrator Partner Network tracks. This broad and deep expertise enables NTT DATA to deliver unique full-stack services, from advisory to deployment and operations.

 

 

Learn more about NVIDIA-powered innovations from NTT DATA here. Learn more about NTT DATA’s full-stack services and solutions at nttdata.com.

 

 

About NTT DATA

 

 

NTT DATA is a $30+ billion business and technology services leader, serving 75% of the Fortune Global 100. We are committed to accelerating client success and positively impacting society through responsible innovation. We are one of the world’s leading AI and digital infrastructure providers, with unmatched capabilities in enterprise-scale AI, cloud, security, connectivity, data centers and application services. Our consulting and industry solutions help organizations and society move confidently and sustainably into the digital future. As a Global Top Employer, we have experts in more than 70 countries. We also offer clients access to a robust ecosystem of innovation centers as well as established and start-up partners. NTT DATA is part of NTT Group, which invests over $3 billion each year in R&D.

 

 

Visit us at nttdata.com.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311112934/en/

 

Business Wire India

The 57^th edition of Media Expo Mumbai 2026, international trade exhibition on indoor and outdoor advertising and signage solutions, is set to take place from 09-11 April 2026 at Bombay Exhibition Centre, Mumbai. The show will establish a convergence of leading global brands and creative professionals and discover path-breaking future technologies. Building on the success of its previous editions, the upcoming show will present a sharper focus on Digital Signage and POP / POSM solutions, reflecting the industry’s shift toward application-led and technology-driven visual communication across retail, branding and OOH segments.

Among the ever-growing digital boom across industries, the billboard and outdoor market have stood strong. According to the Grand View Research, India Billboard and Outdoor Advertising market generated a revenue of USD 576.3 million in 2025 and is expected to reach USD 1,075.5 million by 2033. The market is expected to grow at a CAGR of 8.2%, riding on the growth wave of buildings, a segment with largest revenue generation in 2025. Advertising and branding displays in commercial buildings is emerging as one of the potential application segments for a wide range of indoor and outdoor media.

With India booming with huge infrastructure projects and MSMEs being the key solution providers in the industry, Media Expo Mumbai 2026 becomes more than relevant. Mr Raj Manek, Executive Director & Board Member, Messe Frankfurt Asia Holdings Ltd, said: “Media Expo Mumbai 2026 stands at a pivotal juncture, where new avenues of growth are rapidly unfolding. The industry has decisively embraced digital transformation, aligned itself with sustainable and eco-conscious practices and expanded the scope of signage applications across diverse sectors. From advanced digital signage solutions to innovative interior and exterior décor formats, the evolution underscores the expanding influence and versatility of the signage and OOH media ecosystem.”

With innovation, scale and industry relevance at its core, Media Expo Mumbai 2026 is poised to serve as a dynamic business platform for stakeholders looking to capitalise on India’s expanding advertising, retail and visual communication landscape. Spanning approximately 15,000 sqm of gross exhibition area, Media Expo Mumbai 2026 will host 140+ exhibitors, showcasing 350+ products from nearly 250+ brands.

The show will see the participation from companies like: ADS LED, Aestrik Techno Signs, Arihant Uniglobe, Arrow Digital, Ashwin Enterprises, Britomatics India, CDI Colors Digital, Colorjet India, Cosign India, Epson India, Garware Hi-Tech Films, HP, Jindal Speciality Textile, Laxmi Sales Corporation, Lisco Systems, Maruti Flex Traders, Mehta Hi-tech Industries, Mimaki India, Negi Sign Systems & Supplies Co, Newclear, Navkar Enterprises, Pidilite industries, Suresh Indu Laser, Shakti Acryplast, Shreeji International, Shubh Plastics, Silicon Infotech, Truecolor Solutions & Technologies India, Varay Image Runners and Wonder Signs India, along with several other prestigious companies. The show will see international participation from leading companies across China, Italy, and South Korea.

The show will see international participation from leading companies across China, Italy, and South Korea.

Over the years, the show has seen advances in the categories like digital signage & display technologies; POP / POSM and retail branding solutions; large-format & industrial printing. Moreover, the show has seen growth in segments such as digital signage and LED display systems, POP / POSM fabrication materials, large-format printing machinery, and sign-making and fabrication equipment. These sectors continue to witness strong demand as brands invest in high-impact, immersive and durable display technologies.

Press information and photographic material
https://media-expo-mumbai.in.messefrankfurt.com/mumbai/en.html

For Events & Entertainment Technologies shows worldwide, please visit:
www.prolight-sound.com/worldwide

Background information on Messe Frankfurt
www.messefrankfurt.com/background-information

Sustainability at Messe Frankfurt
www.messefrankfurt.com/sustainability-information

Business Wire India

 

• £65m investment in new oral health manufacturing plant in Shanghai to support growth in the world’s largest gum health market

• Haleon aiming to extend gum health brand parodontax to 30 Chinese cities by end of 2027 – including its fastest growing cities – reaching aspirational shoppers in-store and online

• Custom designed taste, foamier sensation and premium packaging to appeal to local consumers

 

Haleon, a consumer company that is solely focused on better everyday health, is investing £65 million in a new state-of-the-art oral health manufacturing site in Shanghai. The facility will support the expansion of its oral care portfolio – which includes the global brands Sensodyne and parodontax – into China’s fast-growing tier 2 and tier 3 cities, where rising incomes, growing awareness of everyday health and a shift towards trusted, branded products are reshaping consumer behaviour.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311389622/en/

 

 

 

As part of this shift, more consumers are embedding preventative oral care into their daily self-care routines, and demand for premium, science-backed solutions is accelerating at a rapid pace. This investment strengthens Haleon’s local manufacturing footprint and positions the business to capture long-term growth in one of its most dynamic markets.

 

China’s gum health market is the largest in the world, valued at approximately £860 million. With over 70% of adults in China experiencing some form of gum issue and rising awareness of symptoms such as bleeding, redness and tenderness, this presents significant market opportunities for clinically proven gum health products.

 

 

parodontax — Haleon’s fastest-growing oral health brand — is the first toothpaste in China clinically proven to target the root cause of bleeding gums by breaking down stubborn plaque, which is a leading cause of gum disease. However, its distinctive sensory profile, driven by its key active ingredient, sodium bicarbonate, differs from many local toothpastes, which tend to have sweeter or more floral flavour profiles.

 

 

To ensure the product resonates with Chinese consumers, Haleon’s global R&D team worked closely with local sensory scientists to adapt the flavour — balancing the efficacy of the global formulation with sweeter, more fragrant notes and a foamier brushing experience, while maintaining its clinical performance. Premium packaging further highlights its therapeutic, clinically proven benefits in an increasingly sophisticated oral care aisle.

 

 

Haleon is also adopting a multi-channel retail strategy to expand access to parodontax across China. In addition to its rapidly growing presence across e-commerce platforms like Douyin, the company aims to extend parodontax distribution to 30 cities by the end of 2027, bringing the brand within reach of more than 250 million people. These cities are home to a rising middle class with increasing disposable income and appetite for trusted international brands. Large-format club retailers are expanding quickly, while Haleon also maintains a strong presence in retail pharmacies — both in-store and online — supported by a network of dental professionals who regularly recommend its products.

 

 

Brian McNamara, Chief Executive of Haleon, said: “China is a strategic priority for Haleon. Building on our established R&D capabilities and strong local team, this investment reflects our long-term commitment to bringing the very best of our global science and innovation to improve the health and wellbeing of Chinese consumers.

 

 

“By combining our world-class research expertise with deep local insights and on-the-ground manufacturing and R&D capabilities, we are delivering high-quality, science-backed products that improve everyday health in China.”

 

 

The new oral health facility will be located in Shanghai’s Lingang New Area, a fast-growing industrial hub. By bringing supply capacity for China in-house, Haleon aims to respond more quickly to evolving consumer preferences and accelerate innovation in a rapidly growing category — supporting its ambition to reach one billion more consumers by 2030, while generating £800m in gross productivity savings over the next five years through a more agile and efficient supply chain.

 

 

In June 2025, Haleon also completed the full acquisition of its TSKF joint venture with an investment of approximately £700 million, taking direct control of its Over-the-Counter business in China. Together, these investments underline Haleon’s long-term confidence in the growth of China’s consumer healthcare market.

 

 

About Haleon

 

 

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are trusted by more than one billion consumers and are recommended by health professionals around the world.

 

 

For more information, please visit www.haleon.com.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311389622/en/

 

Business Wire India

• The two largest global providers of massive IoT networks partner to provide a combined offering of LoRaWAN^® and Cellular connectivity.
• 1NCE now integrates Netmore’s LoRaWAN into the 1NCE OS platform, allowing customers to use both services seamlessly through its software stack.
• The new network addresses 90% of the LPWAN market and offers an unparalleled ability to eliminate coverage blind spots around the globe

 

1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, today opened access for its customers to the LoRaWAN^® services of Netmore, the world’s leading low power wide area network operator for massive IoT. With growing demand for low power long range connectivity, the Netmore LoRaWAN Network Server (LNS) Plugin provides 1NCE customers access to cellular and LoRaWAN IoT coverage options through one platform.

 

The launch of the Netmore Plugin marks the beginning of strategic collaboration to expand the combined offering of the two biggest massive IoT network specialists — 1NCE, the biggest private IoT network in the cloud and Netmore, the largest LoRaWAN network and platform provider in the world. 1NCE’s software and connectivity platform has become a new industry standard.

 

 

Working together to support their respective customer bases with both cellular and LoRaWAN technology delivers a powerful layer of redundancy to cover the hardest to reach spots with reliable connectivity and IoT services. Through a unified visibility, ingestion and routing software tool, it’s now possible to seamlessly manage both technologies in one place. It’s ideal for use cases such as smart cities, street lighting, logistics, smart metering and other utility applications. An estimated 90% of the market can be served by LPWAN and LoRaWAN by 2028, as forecasted by global technology research and advisory firm Omdia¹.

 

 

“Cellular plus LoRaWAN is an unbeatable package that delivers the best value in IoT,” said Ivo Rook, Co-Chief Executive Officer of 1NCE. “By combining our market-leading LoRaWAN services with 1NCE’s cellular platform, customers can now eliminate coverage gaps, reduce complexity, and deploy low-bandwidth solutions with unprecedented reliability across the world,” said Ove Anebygd, Chief Executive Officer of Netmore Group.

 

 

The Netmore’s LoRaWAN Plugin is now available on the 1NCE platform.

 

 

¹“Low Power Wide Area Network (LPWAN) Market Report – 2023 Data“, Omdia

 

 

About 1NCE

 

 

1NCE delivers the fundamental software and connectivity platform for customers to create and manage the world’s best intelligent products. The software platform enables customers to easily, securely and reliably collect device data across 170+ countries and turn it into actionable intelligence.

 

 

About Netmore

 

 

Netmore Group is the leading global network operator for Massive IoT, powering the world’s most advanced and sustainability-focused solutions for utilities, buildings, cities, and other markets that benefit from sensor-connected environments. Netmore operates in 18 countries and is backed by Nordic infrastructure investor Polar Structure.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311190961/en/

 

Business Wire India

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering.

 

As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma.

 

The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities.

 

The shares will be held in treasury for future use in connection with Galderma’s employee participation plans, business development opportunities and/or treasury management.

“This repurchase reflects our confidence in Galderma’s future growth. Through our unique integrated dermatology strategy, consistent execution and financial discipline, we continue to strengthen our category leadership. This underscores our ambition to build the undisputed dermatology powerhouse, delivering attractive shareholder value creation and continuing to invest for the future.”   FLEMMING ØRNSKOV, M.D., MPH CHIEF EXECUTIVE OFFICER GALDERMA

 

Following the closing of the ABO, the free float in Galderma’s shares is expected to increase from 65% to 80%.

 

About Galderma

 

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

 

Forward-looking statements

 

Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “plans”, “targets”, “aims”, ” believes”, “expects”, “anticipates”, “intends”, “estimates”, “will”, “may”, “continues”, “should” and similar expressions. These forward-looking statements reflect, at the time, Galderma’s beliefs, intentions and current targets/ aims concerning, among other things, Galderma’s results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management’s current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma’s markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310572494/en/

 

Business Wire India

• SkyDefender is a multi-layer, multi-domain Integrated Air and Missile Defence system providing full protection against all types of air threats, on land, at sea and in space.
• SkyDefender integrates a network of advanced sensors and effectors with a versatile command and control (C2) system. With its open and modular architecture, it is fully compatible with existing air defence systems.
• Combining Thales’ expertise in cybersecurity and advanced artificial intelligence through cortAIx, Thales AI accelerator, SkyDefender enables operational superiority and proactive defence against cyberattacks and evolving threats.
• Thales is capable of delivering this critical protection globally from today.

 

As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/en/

 

 

Thales SkyDefender provides full protection against all types of air threats, from a few kilometres to several thousands of kilometres:

• Short-range: for protection of forces, vital assets and sensitive sites: ForceShield creates a real protection bubble against lower layer and surface threats at very short- and short-range, such as drones.
• Medium-range: for protection at theatre-level defence: SAMP-T NG by eurosam¹ with up to 150 km engagement range, including Thales’ powerful Ground Fire radar with 350 km range and 360°/90° coverage against medium-range defence.
• Long-range: for protection against long-range threats with early-warning capabilities: a unique capacity that empowers armed forces with superior tracking, identifying hard-to-find targets including fighter jets and ballistic missiles bolstering Space Domain Awareness. Thales SMART-L MM and UHF radars, which can detect potential threats at distances of up to 5,000 km, are key differentiators. Thales Alenia Space offers an early warning solution from geostationary orbit thanks to satellites equipped with infrared sensors that can detect a missile threat, and give the accurate location of the launch, even before it enters the areas covered by ground-based radars. Combined with the ground-based UHF advanced long-range radars, it provides a unique capability of permanent surveillance, early detection and trajectory follow-up of long-range threats.

 

All elements are managed through Thales’ SkyView command and control (C2) system, with SkyView Alliance ensuring seamless interoperability with NATO and allied multi-domain platforms.

 

Built on an open, modular architecture, SkyDefender integrates easily with existing defences and can be further developed as threats evolve. The development and deployment of the system is open to partnerships with other industrial players.

 

SkyDefender is fully compatible with a wide variety of sensors and weapon systems, including those from different manufacturers and existing legacy platforms.

 

“Thales is proud to contribute to the sovereignty of our nations with SkyDefender, the global air and missile defence dome based on our latest advanced technologies, from counter-drone protection to early warning capacities. With SkyDefender Thales provides a combat-proven system, easy-to-integrate and available today, confirming our position as a long-term trusted partner for the armed forces.” Hervé Dammann, Executive Vice-President, Land and Air Systems, Thales.

 

About Thales

 

Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services helps address several major challenges: sovereignty, security, sustainability and inclusion.

 

The Group allocates €4.5 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, Cybersecurity, Quantum and Cloud technologies.

 

Thales has more than 85,000 employees in 65 countries. In 2025, the Group generated sales of €22.1 billion.

 

PLEASE VISIT
Thales Group
Defence
Thales

 

Recent images of Thales and its Defense, Aerospace and Cyber & Digital activities can be found on the Thales Media Library. For any specific requests, please contact the Media Relations team.

 

1 The SAMP/T NG programme is overseen by the Organisation Conjointe de Coopération en matière d’Armement (OCCAR). Eurosam, a joint-venture between Thales and MBDA, is the lead contractor for the entire system.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310398606/en/